Plasma ACE2 Activity Predicts Mortality in Aortic Stenosis and Is Associated With Severe Myocardial Fibrosis

JACC: Cardiovascular Imaging

Volumn 13, Issue 3, 2020, Pages 655-664

  Ramchand, Jay ^a,b   Patel, Sheila K ^a   Kearney, Leighton G ^b   Matalanis, George ^b   Farouque, Omar ^a,b   Srivastava, Piyush M ^a,b   Burrell, Louise M ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b AUSTIN HEALTH   (Australia)

Author keywords

angiotensin II; cardiac fibrosis; myocardial dysfunction; renin angiotensin system; valve disease

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; BIOLOGICAL MARKER; DIPEPTIDYL CARBOXYPEPTIDASE;

ADULT; AGED; ALL CAUSE MORTALITY; AORTIC STENOSIS; ARTICLE; CARDIOVASCULAR MORTALITY; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; GENE EXPRESSION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART VALVE CALCIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; AORTIC VALVE STENOSIS; BLOOD; CARDIAC MUSCLE; FIBROSIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SEVERITY OF ILLNESS INDEX; UPREGULATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; AORTIC VALVE STENOSIS; BIOMARKERS; FEMALE; FIBROSIS; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PEPTIDYL-DIPEPTIDASE A; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 85073187088     PISSN: 1936878X     EISSN: 18767591     Source Type: Journal    
DOI: 10.1016/j.jcmg.2019.09.005     Document Type: Article

References (35)

1. Otto, C.M., Prendergast, B., Aortic-valve stenosis–from patients at risk to severe valve obstruction. N Engl J Med 371 (2014), 744–756.
2. Baumgartner, H., Falk, V., Bax, J.J., et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J 38 (2017), 2739–2791.
3. Pellikka, P.A., Sarano, M.E., Nishimura, R.A., et al. Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up. Circulation 111 (2005), 3290–3295.
4. Chin, C.W., Shah, A.S., McAllister, D.A., et al. High-sensitivity troponin I concentrations are a marker of an advanced hypertrophic response and adverse outcomes in patients with aortic stenosis. Eur Heart J 35 (2014), 2312–2321.
5. Kearney, L.G., Lu, K., Ord, M., et al. Global longitudinal strain is a strong independent predictor of all-cause mortality in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging 13 (2012), 827–833.
6. Treibel, T.A., Lopez, B., Gonzalez, A., et al. Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur Heart J 39 (2018), 699–709.
7. Epelman, S., Shrestha, K., Troughton, R.W., et al. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15 (2009), 565–571.
8. Ortiz-Perez, J.T., Riera, M., Bosch, X., et al. Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study. PLoS One, 8, 2013, e61695.
9. Ramchand, J., Patel, S.K., Srivastava, P.M., Farouque, O., Burrell, L.M., Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLoS One, 13, 2018, e0198144.
10. Walters, T.E., Kalman, J.M., Patel, S.K., Mearns, M., Velkoska, E., Burrell, L.M., Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling. Europace 19 (2016), 1280–1287.
11. Burrell, L.M., Risvanis, J., Kubota, E., et al. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26 (2005), 369–375.
12. Zulli, A., Burrell, L.M., Buxton, B.F., Hare, D.L., ACE2 and AT4R are present in diseased human blood vessels. Eur J Histochem 52 (2008), 39–44.
13. Lambert, D.W., Yarski, M., Warner, F.J., et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem 280 (2005), 30113–30119.
14. Crackower, M.A., Sarao, R., Oudit, G.Y., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417 (2002), 822–828.
15. Burrell, L.M., Burchill, L., Dean, R.G., Griggs, K., Patel, S.K., Velkoska, E., Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition. Exp Physiol 97 (2012), 477–485.
16. Lew, R.A., Warner, F.J., Hanchapola, I., et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol 93 (2008), 685–693.
17. Baumgartner, H., Hung, J., Bermejo, J., et al. Recommendations on the echocardiographic assessment of aortic valve stenosis: a focused update from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 30 (2017), 372–392.
18. Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 (2015), 1–39 e14.
19. Food and Drug Administration. 510(k) substantial equivalence determination decision summary assay only template. Available at: https://www.accessdata.fda.gov/cdrh_docs/reviews/K060964.pdf. (Accessed 15 November 2018)
20. Clavel, M.A., Malouf, J., Michelena, H.I., et al. B-type natriuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am Coll Cardiol 63 (2014), 2016–2025.
21. Candido, R., Forbes, J.M., Thomas, M.C., et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92 (2003), 785–792.
22. Querejeta, R., Lopez, B., Gonzalez, A., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 110 (2004), 1263–1268.
23. Liu, X., Classification accuracy and cut point selection. Stat Med 31 (2012), 2676–2686.
24. Pencina, M.J., D' Agostino, R.B., D' Agostino, R.B., Vasan, R.S., Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Stat Med 27 (2008), 157–172.
25. Fielitz, J., Hein, S., Mitrovic, V., et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol 37 (2001), 1443–1449.
26. Bull, S., Loudon, M., Francis, J.M., et al. A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur Heart J Cardiovasc Imaging 16 (2015), 834–841.
27. Donoghue, M., Hsieh, F., Baronas, E., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87 (2000), E1–E9.
28. Ferrario, C.M., Angiotensin-converting enzyme 2 and angiotensin-(1-7): an evolving story in cardiovascular regulation. Hypertension 47 (2006), 515–521.
29. Dahou, A., Clavel, M.A., Capoulade, R., et al. B-type natriuretic peptide and high-sensitivity cardiac troponin for risk stratification in low-flow, low-gradient aortic stenosis: a substudy of the TOPAS study. J Am Coll Cardiol Img 11 (2018), 939–947.
30. Lambert, D.W., Clarke, N.E., Hooper, N.M., Turner, A.J., Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. FEBS Lett 582 (2008), 385–390.
31. Patel, V.B., Clarke, N., Wang, Z., et al. Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS. J Mol Cell Cardiol 66 (2014), 167–176.
32. Helske, S., Lindstedt, K.A., Laine, M., et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 44 (2004), 1859–1866.
33. Peltonen, T., Napankangas, J., Ohtonen, P., et al. (Pro)renin receptors and angiotensin converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in human aortic valve stenosis. Atherosclerosis 216 (2011), 35–43.
34. Dweck, M.R., Joshi, S., Murigu, T., et al. Midwall fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol 58 (2011), 1271–1279.
35. Genereux, P., Pibarot, P., Redfors, B., et al. Staging classification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 38 (2017), 3351–3358.